December 2024 – Page 13

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

6 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

Q32 Bio Inc. Faces Market Volatility After Bempikibart Program Update

6 months ago talkbio0Tagged Autoimmune Diseases, bempikibart, Bio Inc., IL-7/TSLP pathways, Market, Performance, Volatility

Q32 Bio Inc., bempikibart, autoimmune diseases, IL-7/TSLP pathways, stock performance, market volatility

BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission

6 months ago talkbio0Tagged Artificial Intelligence, BenevolentAI, biopharmaceutical development, Drug Discovery, Kenneth, Mulvany, Strategic Overhaul, TechBio mission

BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany

Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks

6 months ago talkbio0Tagged Acelyrin, Arthritis, Psoriatic, biotech, Clinical Trials, Failure (biologic function), Hidradenitis, Immunology, IPO, Izokibep, suppurativa

Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO

Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments

6 months ago talkbio0Tagged Angitia Biopharmaceuticals, Antibodies, Bispecific, Clinical Development, Musculoskeletal Diseases, Osteogenesis Imperfecta, Osteoporosis, Series, Spinal fusion (procedure)

Angitia Biopharmaceuticals, Series C funding, Musculoskeletal diseases, Osteoporosis, Osteogenesis imperfecta (OI), Spinal fusion, Bispecific antibodies, Clinical development

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

6 months ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor

Relay Therapeutics Advances PI3K Inhibitor for Breast Cancer Subgroup with Promising Early Trial Results

6 months ago talkbio0Tagged Carcinoma breast stage IV, Clinical Trials, Malignant neoplasm of breast, Mutation, PI3 K inhibitor, PI3Ka, Relay Therapeutics, RLY-2608

Relay Therapeutics, PI3K inhibitor, breast cancer, RLY-2608, metastatic breast cancer, PI3Ka mutations, clinical trial

nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines

6 months ago talkbio0Tagged Biotechnology, Chroma Medicine, epigenetic editing, financing characteristics, genetic medicines, Merger, nChroma, Non-Viral Delivery

nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing

Walgreens Boots Alliance in Negotiations for Potential Sale to Private Equity Firm Sycamore Partners

6 months ago talkbio0Tagged Boots Alliance, Health care facility, Industry, Partner in relationship, Platanus occidentalis whole extract, private equity sale, Walgreens

Walgreens Boots Alliance, Sycamore Partners, private equity sale, retail industry, healthcare retail

From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics

6 months ago talkbio0Tagged Acquisition, allogeneic cell therapy, biotech, CAR-T, Drug Industry, Genetic, genetic medicines, Poseida Therapeutics/ Inc., Roche (company)

Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry